Correction: Western Diet–Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment (The American Journal of Pathology (2017) 187(8) (1800–1813) (S0002944017303139) (10.1016/j.ajpath.2017.04.019));Western Diet–Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment

American Journal of Pathology

Volumn 187, Issue 8, 2017, Pages 1800-1813

  Jena, Prasant K ^a   Sheng, Lili ^a   Liu, Hui Xin ^a   Kalanetra, Karen M ^a   Mirsoian, Annie ^b   Murphy, William J ^b   French, Samuel W ^c   Krishnan, Viswanathan V ^a,d   Mills, David A ^a   Wan, Yu Jui Yvonne ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPICILLIN; AMYLOID ALPHA 1; AMYLOID PROTEIN; BILE ACID; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; CXCL2 CHEMOKINE; DEOXYCHOLIC ACID; ENDOTOXIN; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCODEOXYCHOLIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LITHOCHOLIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; METRONIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOMYCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMYXIN B; PROTEIN; PROTEIN 3 GAMMA; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTEROIDACEAE; BACTEROIDETES; CARBOHYDRATE METABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLOSTRIDIACEAE; CONTROLLED STUDY; DESULFOVIBRIONACEAE; DISEASE SEVERITY; DYSBIOSIS; ENTEROHEPATIC CIRCULATION; FATTY ACID SYNTHESIS; FEMALE; FIRMICUTES; FLOW CYTOMETRY; FRUCTOSE METABOLISM; GENE EXPRESSION; GENE SEQUENCE; HELICOBACTERACEAE; HEPATITIS; INTESTINE FLORA; LACHNOSPIRACEAE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PORPHYROMONADACEAE; PRIORITY JOURNAL; PROTEOBACTERIA; SEX DIFFERENCE; STEATOSIS; STREPTOCOCCACEAE; TRYPTOPHAN METABOLISM; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; FATTY LIVER; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; LIVER; LYMPHOCYTE; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DIET, WESTERN; DYSBIOSIS; FATTY LIVER; INFLAMMATION; LIVER; LYMPHOCYTES; MALE; MICE; MICE, KNOCKOUT; MICROBIOTA; NEUTROPHIL INFILTRATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85023167727     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2017.08.004     Document Type: Erratum

References (75)

1. Wustefeld, T., Rakemann, T., Kubicka, S., Manns, M.P., Trautwein, C., Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology 32 (2000), 514–522.
2. Gabele, E., Dostert, K., Hofmann, C., Wiest, R., Scholmerich, J., Hellerbrand, C., Obermeier, F., DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 55 (2011), 1391–1399.
3. Liu, H.X., Keane, R., Sheng, L., Wan, Y.J., Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol 63 (2015), 1502–1510.
4. Bechmann, L.P., Hannivoort, R.A., Gerken, G., Hotamisligil, G.S., Trauner, M., Canbay, A., The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56 (2012), 952–964.
5. Xu, R., Huang, H., Zhang, Z., Wang, F.S., The role of neutrophils in the development of liver diseases. Cell Mol Immunol 11 (2014), 224–231.
6. Tsuei, J., Chau, T., Mills, D., Wan, Y.J., Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) 239 (2014), 1489–1504.
7. Allen, K., Jaeschke, H., Copple, B.L., Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 178 (2011), 175–186.
8. Bjursell, M., Wedin, M., Admyre, T., Hermansson, M., Bottcher, G., Goransson, M., Linden, D., Bamberg, K., Oscarsson, J., Bohlooly, Y.M., Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One, 8, 2013, e64721.
9. Chiang, J.Y., Bile acid metabolism and signaling. Compr Physiol 3 (2013), 1191–1212.
10. Guo, C., Xie, S., Chi, Z., Zhang, J., Liu, Y., Zhang, L., Zheng, M., Zhang, X., Xia, D., Ke, Y., Lu, L., Wang, D., Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity, 45, 2016, 944.
11. Liu, H.X., Rocha, C.S., Dandekar, S., Wan, Y.J., Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration. J Hepatol 64 (2016), 641–650.
12. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47 (2006), 241–259.
13. Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., Angelin, B., Hyotylainen, T., Oresic, M., Backhed, F., Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
14. Zhang, L., Xie, C., Nichols, R.G., Chan, S.H., Jiang, C., Hao, R., Smith, P.B., Cai, J., Simons, M.N., Hatzakis, E., Maranas, C.D., Gonzalez, F.J., Patterson, A.D., Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism. mSystems, 1, 2016 e00070-16.
15. Torres, J., Bao, X., Iuga, A.C., Chen, A., Harpaz, N., Ullman, T., Cohen, B.L., Pineton de Chambrun, G., Asciutti, S., Odin, J.A., Sachar, D.B., Gaskins, H.R., Setchell, K., Colombel, J.F., Itzkowitz, S.H., Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis 19 (2013), 275–282.
16. Huang, X.F., Zhao, W.Y., Huang, W.D., FXR and liver carcinogenesis. Acta Pharmacol Sin 36 (2015), 37–43.
17. Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D.D., Huang, W., Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67 (2007), 863–867.
18. Li, F., Jiang, C., Krausz, K.W., Li, Y., Albert, I., Hao, H., Fabre, K.M., Mitchell, J.B., Patterson, A.D., Gonzalez, F.J., Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun, 4, 2013, 2384.
19. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S.G., Albert, I., Patterson, A.D., Gonzalez, F.J., Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125 (2015), 386–402.
20. Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J.M., Gonzalez, F.J., Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28 (2007), 940–946.
21. Liu, N., Meng, Z., Lou, G., Zhou, W., Wang, X., Zhang, Y., Zhang, L., Liu, X., Yen, Y., Lai, L., Forman, B.M., Xu, Z., Xu, R., Huang, W., Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol Endocrinol 26 (2012), 775–785.
22. Sinal, C.J., Tohkin, M., Miyata, M., Ward, J.M., Lambert, G., Gonzalez, F.J., Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000), 731–744.
23. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council. Guide for the Care and Use of Laboratory Animals. ed 8, 2011, National Academies Press, Washington, DC.
24. Ooi, J.H., Li, Y., Rogers, C.J., Cantorna, M.T., Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 143 (2013), 1679–1686.
25. Pappo, I., Becovier, H., Berry, E.M., Freund, H.R., Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 51 (1991), 106–112.
26. Frese, S.A., Parker, K., Calvert, C.C., Mills, D.A., Diet shapes the gut microbiome of pigs during nursing and weaning. Microbiome, 3, 2015, 28.
27. Bokulich, N.A., Thorngate, J.H., Richardson, P.M., Mills, D.A., Microbial biogeography of wine grapes is conditioned by cultivar, vintage, and climate. Proc Natl Acad Sci U S A 111 (2014), E139–E148.
28. Bokulich, N.A., Collins, T.S., Masarweh, C., Allen, G., Heymann, H., Ebeler, S.E., Mills, D.A., Associations among wine grape microbiome, metabolome, and fermentation behavior suggest microbial contribution to regional wine characteristics. MBio, 7, 2016 e00631-16.
29. Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D., Costello, E.K., Fierer, N., Pena, A.G., Goodrich, J.K., Gordon, J.I., Huttley, G.A., Kelley, S.T., Knights, D., Koenig, J.E., Ley, R.E., Lozupone, C.A., McDonald, D., Muegge, B.D., Pirrung, M., Reeder, J., Sevinsky, J.R., Turnbaugh, P.J., Walters, W.A., Widmann, J., Yatsunenko, T., Zaneveld, J., Knight, R., QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7 (2010), 335–336.
30. Langille, M.G.I., Zaneveld, J., Caporaso, J.G., McDonald, D., Knights, D., Reyes, J.A., Clemente, J.C., Burkepile, D.E., Vega Thurber, R.L., Knight, R., Beiko, R.G., Huttenhower, C., Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 31 (2013), 814–821.
31. Cox, M.A., Jackson, J., Stanton, M., Rojas-Triana, A., Bober, L., Laverty, M., Yang, X., Zhu, F., Liu, J., Wang, S., Monsma, F., Vassileva, G., Maguire, M., Gustafson, E., Bayne, M., Chou, C.C., Lundell, D., Jenh, C.H., Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol 15 (2009), 5549–5557.
32. Dvorak, K., Chavarria, M., Payne, C.M., Ramsey, L., Crowley-Weber, C., Dvorakova, B., Dvorak, B., Bernstein, H., Holubec, H., Sampliner, R.E., Bernstein, C., Prasad, A., Green, S.B., Garewal, H., Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res 13 (2007), 5305–5313.
33. Ji, Y.R., Kim, H.J., Bae, K.B., Lee, S., Kim, M.O., Ryoo, Z.Y., Hepatic serum amyloid A1 aggravates T cell-mediated hepatitis by inducing chemokines via Toll-like receptor 2 in mice. J Biol Chem 290 (2015), 12804–12811.
34. Xu, L., Badolato, R., Murphy, W.J., Longo, D.L., Anver, M., Hale, S., Oppenheim, J.J., Wang, J.M., A novel biologic function of serum amyloid A: induction of T lymphocyte migration and adhesion. J Immunol 155 (1995), 1184–1190.
35. Badolato, R., Wang, J.M., Murphy, W.J., Lloyd, A.R., Michiel, D.F., Bausserman, L.L., Kelvin, D.J., Oppenheim, J.J., Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180 (1994), 203–209.
36. Amoras Eda, S., Gomes, S.T., Freitas, F.B., Santana, B.B., Ishak, G., Ferreira de Araujo, M.T., Demachki, S., Conde, S.R., Ishak Mde, O., Ishak, R., Vallinoto, A.C., Intrahepatic mRNA expression of FAS, FASL, and FOXP3 genes is associated with the pathophysiology of chronic HCV infection. PLoS One, 11, 2016, e0156604.
37. Riezu-Boj, J.I., Larrea, E., Aldabe, R., Guembe, L., Casares, N., Galeano, E., Echeverria, I., Sarobe, P., Herrero, I., Sangro, B., Prieto, J., Lasarte, J.J., Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J Hepatol 54 (2011), 422–431.
38. Heiseke, A.F., Faul, A.C., Lehr, H.A., Forster, I., Schmid, R.M., Krug, A.B., Reindl, W., CCL17 promotes intestinal inflammation in mice and counteracts regulatory T cell-mediated protection from colitis. Gastroenterology 142 (2012), 335–345.
39. Belperio, J.A., Dy, M., Murray, L., Burdick, M.D., Xue, Y.Y., Strieter, R.M., Keane, M.P., The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 173 (2004), 4692–4698.
40. Santulli-Marotto, S., Boakye, K., Lacy, E., Wu, S.J., Luongo, J., Kavalkovich, K., Coelho, A., Hogaboam, C.M., Ryan, M., Engagement of two distinct binding domains on CCL17 is required for signaling through CCR4 and establishment of localized inflammatory conditions in the lung. PLoS One, 8, 2013, e81465.
41. Affo, S., Morales-Ibanez, O., Rodrigo-Torres, D., Altamirano, J., Blaya, D., Dapito, D.H., Millan, C., Coll, M., Caviglia, J.M., Arroyo, V., Caballeria, J., Schwabe, R.F., Gines, P., Bataller, R., Sancho-Bru, P., CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63 (2014), 1782–1792.
42. Loonen, L.M., Stolte, E.H., Jaklofsky, M.T., Meijerink, M., Dekker, J., van Baarlen, P., Wells, J.M., REG3gamma-deficient mice have altered mucus distribution and increased mucosal inflammatory responses to the microbiota and enteric pathogens in the ileum. Mucosal Immunol 7 (2014), 939–947.
43. Aminov, R.I., Walker, A.W., Duncan, S.H., Harmsen, H.J., Welling, G.W., Flint, H.J., Molecular diversity, cultivation, and improved detection by fluorescent in situ hybridization of a dominant group of human gut bacteria related to Roseburia spp. or Eubacterium rectale. Appl Environ Microbiol 72 (2006), 6371–6376.
44. Plöger, S., Stumpff, F., Penner, G.B., Schulzke, J.D., Gäbel, G., Martens, H., Shen, Z., Günzel, D., Aschenbach, J.R., Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci 1258 (2012), 52–59.
45. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111 (2014), 2247–2252.
46. Morotomi, M., Nagai, F., Watanabe, Y., Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov. Int J Syst Evol Microbiol 62 (2012), 144–149.
47. Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J.T., Spector, T.D., Clark, A.G., Ley, R.E., Human genetics shape the gut microbiome. Cell 159 (2014), 789–799.
48. Korpela, K., Flint, H.J., Johnstone, A.M., Lappi, J., Poutanen, K., Dewulf, E., Delzenne, N., de Vos, W.M., Salonen, A., Gut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals. PLoS One, 9, 2014, e90702.
49. Smit, B.A., van Hylckama Vlieg, J.E., Engels, W.J., Meijer, L., Wouters, J.T., Smit, G., Identification, cloning, and characterization of a Lactococcus lactis branched-chain alpha-keto acid decarboxylase involved in flavor formation. Appl Environ Microbiol 71 (2005), 303–311.
50. Al-Gwaiz, L.A., Babay, H.H., The diagnostic value of absolute neutrophil count, band count and morphologic changes of neutrophils in predicting bacterial infections. Med Princ Pract 16 (2007), 344–347.
51. Golden-Mason, L., Palmer, B.E., Kassam, N., Townshend-Bulson, L., Livingston, S., McMahon, B.J., Castelblanco, N., Kuchroo, V., Gretch, D.R., Rosen, H.R., Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83 (2009), 9122–9130.
52. Jones, R.B., Ndhlovu, L.C., Barbour, J.D., Sheth, P.M., Jha, A.R., Long, B.R., Wong, J.C., Satkunarajah, M., Schweneker, M., Chapman, J.M., Gyenes, G., Vali, B., Hyrcza, M.D., Yue, F.Y., Kovacs, C., Sassi, A., Loutfy, M., Halpenny, R., Persad, D., Spotts, G., Hecht, F.M., Chun, T.W., McCune, J.M., Kaul, R., Rini, J.M., Nixon, D.F., Ostrowski, M.A., Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205 (2008), 2763–2779.
53. Massafra, V., Ijssennagger, N., Plantinga, M., Milona, A., Ramos Pittol, J.M., Boes, M., van Mil, S.W.C., Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim Biophys Acta 1862 (2016), 166–173.
54. Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., Fiorucci, S., The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183 (2009), 6251–6261.
55. Hu, Y., Chau, T., Liu, H.X., Liao, D., Keane, R., Nie, Y., Yang, H., Wan, Y.J., Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis. Mol Cancer Res 13 (2015), 281–292.
56. Dai, J., Wang, H., Shi, Y., Dong, Y., Zhang, Y., Wang, J., Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol, 4, 2011, 41.
57. Willart, M.A., van Nimwegen, M., Grefhorst, A., Hammad, H., Moons, L., Hoogsteden, H.C., Lambrecht, B.N., Kleinjan, A., Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy 67 (2012), 1501–1510.
58. Ley, R.E., Backhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102 (2005), 11070–11075.
59. Turnbaugh, P.J., Backhed, F., Fulton, L., Gordon, J.I., Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3 (2008), 213–223.
60. De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., Marzioni, M., Benedetti, A., Svegliati-Baroni, G., Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59 (2014), 1738–1749.
61. Chen, J., Chia, N., Kalari, K.R., Yao, J.Z., Novotna, M., Soldan, M.M., Luckey, D.H., Marietta, E.V., Jeraldo, P.R., Chen, X., Weinshenker, B.G., Rodriguez, M., Kantarci, O.H., Nelson, H., Murray, J.A., Mangalam, A.K., Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep, 6, 2016, 28484.
62. Labbe, A., Ganopolsky, J.G., Martoni, C.J., Prakash, S., Jones, M.L., Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes. PLoS One, 9, 2014, e115175.
63. Gevers, D., Kugathasan, S., Denson Lee, A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song Se, J., Yassour, M., Morgan Xochitl, C., Kostic Aleksandar, D., Luo, C., González, A., McDonald, D., Haberman, Y., Walters, T., Baker, S., Rosh, J., Stephens, M., Heyman, M., Markowitz, J., Baldassano, R., Griffiths, A., Sylvester, F., Mack, D., Kim, S., Crandall, W., Hyams, J., Huttenhower, C., Knight, R., Xavier Ramnik, J., The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392.
64. Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., Moschetta, A., Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7 (2014), 12–18.
65. Nishitani, Y., Tanoue, T., Yamada, K., Ishida, T., Yoshida, M., Azuma, T., Mizuno, M., Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int Immunopharmacol 9 (2009), 1444–1451.
66. Ryan, K.K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Perez, H.E., Sandoval, D.A., Kohli, R., Backhed, F., Seeley, R.J., FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
67. Ijssennagger, N., Belzer, C., Hooiveld, G.J., Dekker, J., van Mil, S.W., Muller, M., Kleerebezem, M., van der Meer, R., Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci U S A 112 (2015), 10038–10043.
68. Attene-Ramos, M.S., Wagner, E.D., Plewa, M.J., Gaskins, H.R., Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 4 (2006), 9–14.
69. Gibson, G.R., Cummings, J.H., Macfarlane, G.T., Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Ecol 9 (1991), 103–111.
70. Loubinoux, J., Bisson-Boutelliez, C., Miller, N., Le Faou, A.E., Isolation of the provisionally named Desulfovibrio fairfieldensis from human periodontal pockets. Oral Microbiol Immunol 17 (2002), 321–323.
71. Hagiwara, S., Yoshida, A., Omata, Y., Tsukada, Y., Takahashi, H., Kamewada, H., Koike, S., Okuzumi, K., Hishinuma, A., Kobayashi, K., Nakano, M., Desulfovibrio desulfuricans bacteremia in a patient hospitalized with acute cerebral infarction: case report and review. J Infect Chemother 20 (2014), 274–277.
72. Tee, W., Dyall-Smith, M., Woods, W., Eisen, D., Probable new species of Desulfovibrio isolated from a pyogenic liver abscess. J Clin Microbiol 34 (1996), 1760–1764.
73. Nambiar, P.R., Kirchain, S., Fox, J.G., Gastritis-associated adenocarcinoma and intestinal metaplasia in a Syrian hamster naturally infected with Helicobacter species. Vet Pathol 42 (2005), 386–390.
74. Fox, J.G., Li, X., Yan, L., Cahill, R.J., Hurley, R., Lewis, R., Murphy, J.C., Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of helicobacter-induced carcinogenesis. Infect Immun 64 (1996), 1548–1558.
75. Wexler, H.M., Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20 (2007), 593–621.